nach oben

Erschienen in:

25.10.2017 | Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

verfasst von: Guillermina Isla, Constanza G. Taverna, Wanda Szusz, Walter Vivot, Guillermo García-Effron, Graciela Davel

Erschienen in: Current Fungal Infection Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This review summarizes the information available of Candida haemulonii sensu lato, and updates the in vitro susceptibility profile of the isolates of these species from Argentina. C. haemulonii sensu lato causes fungemia in low frequency in adults and children; however, the knowledge about this emerging yeast is relevant since it is considered as a multi-resistant pathogen.

Recent findings

The discovery of new antifungal molecules, the determination of epidemiological cutoff value and clinical breakpoints for some yeasts of clinical impact, and the update of techniques to determine the in vitro susceptibility profile to yeast have generated some available information, although, for C. haemulonii sensu lato, this information is not always useful for clinical application.

Summary

We determined the susceptibility profile of C. haemulonii sensu lato strains isolated in Argentina, as a first step to establish the epidemiological cutoff values in our region. We also review the current situation in other countries.

Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol. 2012;50:3641–51.CrossRefPubMedPubMedCentral

Almeida JN Jr, Motta AL, Rossi F, Abdala E, Pierrotti LC, et al. First report of a clinical isolate of Candida haemulonii in Brazil. Clinics. 2012;67:1229–31.CrossRefPubMedPubMedCentral

Khan ZU, Al-Sweih NA, Ahmad S, Al-Kazemi N, Khan S, Joseph L, et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole and fluconazole. Clin Microbiol. 2007;45:2025–7.CrossRef

Muro MD, Motta F de A, Burger M, Melo AS, Dalla-Costa LM. Echinocandin resistance in two Candida haemulonii isolates from pediatric patients. J Clin Microbiol. 2012;50:3783–5.

Silva CM, Carvalho-Parahym AM, Macêdo DP, Lima-Neto RG, Francisco EC, Melo AS, et al. Neonatal candidemia caused by Candida haemulonii: case report and review of literature. Mycopathologia. 2015;180:69–73.CrossRefPubMed

Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infec Diseases. 2009;48:57–61.CrossRef

Crouzet J, Sotto A, Picard E, Lachaud L, Bourgeois N. A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile. Clin Microbiol Infect. 2011;17:1068–70.CrossRefPubMed

Yuvaraj A, Rohit A, Koshy PJ, Nagarajan P, Nair S, Abraham G. Rare occurrence of fatal Candida haemulonii peritonitis in a diabetic CAPD patient. Ren Fail. 2014;36:1466–7.CrossRefPubMed

Fang SY, Wei KC, Chen WC, Lee SJ, Yang KC, Wu CS, et al. Primary deep cutaneous candidiasis caused by Candida duobushaemulonii in a 68-year-old man: the first case report and literature review. Mycoses. 2016;Sep:1–4.

10.

• Kumar A, Prakash A, Singh A, Kumar H, Hagen F, Meis JF, et al. Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerg Microbes Infect. 2016;25-5:e49. This work contains an important number of strains, and the determination of the MICs was performed following a reference methodology.

11.

Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919–26.CrossRefPubMed

12.

• Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53:1823–30. This work contains an important number of strains, and the determination of the MICs was performed following a standard reference method. CrossRefPubMedPubMedCentral

13.

Hou X, Xiao M, Chen SC, Wang H, Cheng JW, Chen XX, et al. Identification and antifungal susceptibility profiles of Candida haemulonii species complex clinical isolates from a multicenter study in China. J Clin Microbiol. 2016;54:2676–80.CrossRefPubMedPubMedCentral

14.

Grenfell RC, da Silva Junior AR, Del Negro GM, Munhoz RB, Gimenes VM, Assis DM, et al. Identification of Candida haemulonii complex species: use of ClinProTools™ to overcome limitations of the Bruker Biotyper™, VITEK MS™ IVD, and VITEK MS™ RUO databases. Front Microbiol. 2016;7:940.CrossRefPubMedPubMedCentral

15.

Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155–65.CrossRefPubMedPubMedCentral

16.

Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J Clin Microbiol. 2017;55:2445–52.CrossRefPubMedPubMedCentral

17.

Oh BJ, Shin JH, Kim MN, Sung H, Lee K, et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol. 2011;49:98–102.CrossRefPubMed

18.

Rodero L, Cuenca-Estrella M, Córdoba S, Cahn P, Davel G, Kaufman S, et al. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol. 2002;40:2266–9.CrossRefPubMedPubMedCentral

19.

Cordoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, Murisengo O, et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol. 2011;43:176–85.PubMed

20.

Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8:e59373.CrossRefPubMedPubMedCentral

21.

• Santolaya ME, Alvarado T, Queiroz-Telles F, Colombo AL, Zurita J, Tiraboschi IN, et al. Latin American Invasive Mycosis Network. Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J. 2014;33:e40–4. This study was conducted in Latin American countries in children provides information about the epidemiology of yeast infections in region. CrossRefPubMed

22.

Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195–203.CrossRefPubMedCentral

23.

Guinea J, Zaragoza O, Escribano P, Martin-Mazuelos E, Peman J, Sanchez-Reus F, et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother. 2014;58:1529–37.CrossRefPubMedPubMedCentral

24.

Faria-Ramos I, Neves-Maia J, Ricardo E, Santos-Antunes J, Silva AT, Costa-de-Oliveira S, et al. Erratum to: species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis. 2015;34:2137.CrossRefPubMed

25.

Minea B, Nastasa V, Moraru RF, Kolecka A, Flonta MM, Marincu I, et al. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis. 2015;34:367–83.CrossRefPubMed

26.

Meletiadis J, Geertsen E, Curfs-Breuker I, Meis JF, Mouton JW. Intra- and interlaboratory agreement in assessing the in vitro activity of micafungin against common and rare Candida species with the EUCAST, CLSI, and Etest methods. Antimicrob Agents Chemother. 2016;60:6173–8.CrossRefPubMedPubMedCentral

27.

Nucci M, Thompson-Moya L, Guzman-Blanco M, Tiraboschi IN, Cortes JA, Echevarría J, et al. Grupo Proyecto Épico. Recommendations for the management of candidemia in adults in Latin America. Grupo Proyecto Épico. Rev Iberoam Micol. 2013;30:179–88.

28.

Santolaya ME, de Queiroz Telles F, Alvarado Matute T, Colombo AL, Zurita J, Tiraboschi IN, et al. Recommendations for the management of candidemia in children in Latin America. Rev Iberoam Micol. 2013;30:171–8.

29.

•• Pappas PG, Kauffman CA, Andes D, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:1–50. Last update of therapeutic guidelines of candidiasis.

30.

•• European Committee for Antimicrobial Susceptibility Testing (EUCAST) Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts, Eucast Definitive Document E.Def 7.3 January 2017. Methodology applied in this work.

31.

• European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antifungal Agents. Breakpoint tables for interpretation of MICs Version 8.1 valid from 2017–03-01 www.eucast.org 2017;1–5. Current Clinical Breakpoint used for the interpretation of MICs.

32.

Kurtzman CP, Fell JW, Boekhout T, editors. The yeast: a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011.

33.

Taverna CG, Bosco-Borgeat ME, Murisengo OA, Davel G, Boité MC, Cupolillo E, et al. Comparative analyses of classical phenotypic method and ribosomal RNA gene sequencing for identification of medically relevant Candida species. Mem Inst Oswaldo Cruz. 2013;108:178–85.CrossRefPubMedPubMedCentral

34.

Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, et al. and Fungal Barcoding Consortium Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci U S A. 2012;109:6241–6.CrossRefPubMedPubMedCentral

35.

Ciardo DE, Schär G, Böttger EC, Altwegg M, Bosshard PP. Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts. J Clin Microbiol. 2006;44:77–84.CrossRefPubMedPubMedCentral

36.

Nilsson RH, Kristiansson E, Ryberg M, Hallenberg N, Larsson KH. Intraspecific ITS variability in the kingdom Fungi as expressed in the international sequence databases and its implications for molecular species identification. Evol Bioinformatics Online. 2008;4:193–201.

37.

Kurtzman CP, Piskur J 2005. Taxonomy and phylogenetic diversity among the yeasts. Top Curr Genet 15.

38.

Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect. 2014;20:698–705.CrossRefPubMed

39.

Ruan SY, Kuo YW, Huang CT, Hsiue HC, Hsueh PR. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Antimicrob Agents. 2010;35:85–8.CrossRef

40.

Shin JH, Kim MN, Jang SJ, MY J, Kim SH, Shin MG, et al. Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J Clin Microbiol. 2012;50:1852–5.CrossRefPubMedPubMedCentral

41.

Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305–12.CrossRefPubMedPubMedCentral

42.

• Ramos LS, Figueiredo-Carvalho MH, Barbedo LS, Ziccardi M, Chaves AL, Zancopé-Oliveira RM, et al. Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. J Antimicrob Chemother. 2015;70(1):111–5. This work contains a significant number of strain; the determination of MICs was developed following a reference methodology and provides the profile of antifungal susceptibility of circulating strains in Latin America. CrossRefPubMed

43.

• de Almeida JN Jr, Assy JG, Levin AS, Del Negro GM, Giudice MC, Tringoni MP, et al. Candida haemulonii Complex Species, Brazil, January 2010–March 2015. Emerg Infect Dis. 2016;22:561–3. This work contains a significant number of strains; the determination of MICs was developed following a reference methodology and provides the profile of susceptibility of circulating strains in Latin America. CrossRefPubMed

44.

Sugita T, Takashima M, Poonwan N, Mekha N. Candida pseudohaemulonii sp. nov., an amphotericin B-and azole-resistant yeast species, isolated from the blood of a patient from Thailand. MicrobiolImmunol. 2006;50:469–73.

45.

Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;24:61.

Titel: Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review
verfasst von: Guillermina Isla
Constanza G. Taverna
Wanda Szusz
Walter Vivot
Guillermo García-Effron
Graciela Davel
Publikationsdatum: 25.10.2017
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 4/2017
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-017-0300-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

A Comprehensive Analysis of MALDI-TOF MS and Ribosomal DNA Sequencing for Identification of Clinical Yeasts

Heteroresistance to Fluconazol in Clinical and Environmental Brazilian Strains of Cryptococcus neoformans/C. gattii Species Complex

What Is New? Recent Knowledge on Fungal Extracellular Vesicles

The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach

Contribution of the National Mycology Laboratory Network to Surveillance of Cryptococcosis in Argentina

Onychomycosis and Immunodepression

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin